Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report - Top-Institutions - MDSpire

Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report

By
Ke Li
Juanjuan Hu
Zhiji Gan
Jiao Chen
Ye Tian
Ruiqing Luo
Xueliang Qi
July 15, 2026

Frontiers In Immunology

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

#1

Johns Hopkins Hospital

Baltimore, Maryland
Key Differentiators
- Neurology
- Myasthenia Gravis
- Myositis
#2

Mayo Clinic

Rochester, Minnesota
Key Differentiators
- Neurology
- Myasthenia Gravis
#3

Peking University First Hospital

Beijing, China
Key Differentiators
- Neurology
#4

First Affiliated Hospital of Zhengzhou University

Zhengzhou, China
Key Differentiators
- Neurology
#5

University of Oklahoma

Oklahoma City, Oklahoma
Key Differentiators
- Neurology

Original Source(s)

Frontiers In Immunology

Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report

by Ke Li, Juanjuan Hu, Zhiji Gan, Jiao Chen, Ye Tian, Ruiqing Luo, Xueliang Qi
July 15, 2026

Related Content

Frontiers In Oncology

Interpretable machine learning-driven multi-omics risk stratification and drug repurposing nominates Treg/Th17 with gluconeogenesis/lactylation integration as a prognostic and druggable biomarker for glioblastoma patients

by Siqi Xie, Weiming Chen, Bing Zhang, Shangeng Weng
July 14, 2026

Frontiers In Neurology

Dynamic frailty and depressive symptoms in relation to incident stroke: findings from five harmonized longitudinal cohorts

by Yicheng Jiang, Qi Wang, Jinsen Zhang, Ming Shan, Qinglong Guo
July 14, 2026

Frontiers In Oncology

Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming

by Egiroh Omene
July 14, 2026